Entries |
Document | Title | Date |
20080213284 | RECEPTOR BINDING POLYPEPTIDES - Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed. | 09-04-2008 |
20080219999 | Immunoadhesin for the prevention of rhinovirus infection - The immunoadhesions of the present invention are useful in treating rhinovirus infections. The immunoadhesions contain a chimeric ICAM molecule and may optionally also contain J chain and secretory compounds. The chimeric ICAM molecule is a fusion protein that has a rhinovirus receptor protein linked to an immunoglobulin protein. This invention also includes the greatly increased and improved method of producing immunoadhesions in plants. Each of the components of an immunoadhesin is produced in a plant cell and thereby assembles within the plant cell. This method of producing the immunoadhesions of the present invention results in the efficient and economic production of these molecules. The present invention also contemplates the production of immunoadhesions in a variety of eukaryotic cells including plants and mammalian cells. The immunoadhesions of the present invention are useful as a therapeutic against the common cold in humans which is caused by rhinoviruses. | 09-11-2008 |
20080299131 | Anti-Viral Compositions - The invention provides a composition comprising for simultaneous, sequential or separate administration a) a polyanion; and b) an antibody reactive against an antigen on the surface of an intracellular form of a virus, which virus has an extracellular form that is surrounded by one lipid membrane more than the intracellular form. The present inventors have found that the compositions according to the invention comprising an antibody and a polyanion can neutralize virus infectivity more efficiently than other compositions reported hitherto. | 12-04-2008 |
20080317761 | Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage - A pharmaceutical composition comprises a therapeutic peptide or protein, a transport moiety capable of transporting said first peptide or protein into a hematopoietic cell differentiated from a common myeloid progenitor, and a linker between said first protein and said transport moiety, said linker susceptible to cleavage by an intracellular enzyme in the cell. A cell or collection of cells, e.g., platelets, containing such a composition is useful in methods for treating infection, inflammation, vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage. Methods of making such compostions are also disclosed. | 12-25-2008 |
20090004203 | METHODS OF TREATING MEASLES INFECTIOUS DISEASE IN MAMMALS - The invention provides for a measles vaccine utilizing a human codon-optimized polynucleotide encoding a measles virus polypeptide, such as HA or F protein. Optionally, the vaccine is administered with an adjuvant and is especially useful for immunizing an infant mammal. | 01-01-2009 |
20090022735 | Receptor Binding Polypeptides - Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed. | 01-22-2009 |
20090041780 | Concentrate of Immunoglobulins and F(ab)'2 and/or Fab Fragments Specific of an Arbovirus as a Medicinal Product - The invention concerns a new medicinal product for the treatment of arboviruses, i.e a concentrate of immunoglobulins and F(ab)′2 and/or Fab fragments specific to said arbovirus as well as its process of preparation. | 02-12-2009 |
20090041781 | METHODS FOR DETECTING PARVOVIRUS INFECTIONS - The present invention provides a method for diagnosing a subject suffering a pathological condition characterized by parvovirus infection by detecting the presence of IgE anti-Parvovirus B 19 antibodies. | 02-12-2009 |
20090074792 | Compositions containing full-length L1R nucleic acid and endoplasmic reticulum-targeting sequence, and methods of use - The invention described here encompasses DNA and protein vaccines against poxviruses, and relevant immunogenic compositions, comprising at a minimum a nucleic acid encoding a modified full-length poxvirus L1R gene or its ortholog. The L1R gene is modified so that an endoplasmic reticulum-targeting sequence is operably linked on the 5′ end. Preferably the nucleic acid sequences for other poxviruses antigens are also included, such as A33R, B5R and/or A27L. These vaccines and compositions provide improved neutralizing antibody response elicited by molecular poxvirus vaccines, over known vaccines using unmodified L1R. | 03-19-2009 |
20090098143 | VACCINE PRODUCTION FOR PATHOGENIC BIRD VIRAL DISEASES - The present invention is an improved method for the production of vaccines to transmittable viral pathogens where the virus is pathogenic to the chicken embryos. Bird embryos are selected for vaccine production from wild and domestic birds, and preferably waterfowl, that have increased resistant to the viral pathogen. The invention is useful for native and engineered viruses. | 04-16-2009 |
20090110684 | Neutralizing monoclonal antibodies to respiratory syncytial virus - The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention. | 04-30-2009 |
20090130123 | Antibodies to west nile virus polypeptides - The present invention relates to anti-West Nile virus E protein (WNE) antibodies, including human antibodies, and antigen-binding portions thereof. In particular, the invention relates to such antibodies and portions that prevent, inhibit, or treat a flavivirus infection, including a West Nile Virus infection. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or that are portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-WNE antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-WNE antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis, prophylaxis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-WNE antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention. | 05-21-2009 |
20090162378 | ANTI-HUMAN CYTOMEGALOVIUS ANTIBODIES - The present invention features a human antibody that specifically binds to human cytomegalovirus (HCMV), its encoding nucleic acid(s), and use of the antibody/nucleic acid(s) in treating HCMV infection. | 06-25-2009 |
20090169566 | BIOACTIVE COMPOSITIONS - This invention relates to a bioactive composition comprising: (d) pH sensitive bioactive agent (e) an edible carboxylic acid containing moiety and (f) an edible alkalising moiety, wherein the proportion of said moieties and active agent provide pH control such that (i) when 400 mg of said composition is added to 20 ml of 0.033 normal hydrochloric acid and at a temperature of 37+/−3° C., the pH reaches a value in the range 4 to 8, and (ii) when 400 mg of said composition is added to 20 ml of deionised water at pH 7 and at a temperature of 37+/−3° C., the pH reaches a value less than 8.5. | 07-02-2009 |
20090175883 | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations - The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention. | 07-09-2009 |
20090252745 | Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis - The presently disclosed subject matter provides methods and compositions for predicting a tendency of a subject infected with hepatitis C virus (HCV) to develop steatosis. In some embodiments, the disclosed methods include the steps of (a) isolating from the subject a biological sample comprising an HCV Core polypeptide or a nucleic acid molecule encoding an HCV Core polypeptide; and (b) identifying the amino acids in the HCV Core polypeptide or encoded by the nucleic acid molecule in the biological sample corresponding to positions 182/186 of an HCV Core polypeptide amino acid sequence, whereby a tendency to develop steatosis in the subject is predicted when the amino acids corresponding to positions 182/186 of the HCV Core polypeptide amino acid sequence in the biological sample are either phenylalanine/valine or leucine/isoleucine. Also provided are compositions and methods for screening for candidate modulators of lipid accumulation in a subject as well as uses for the candidate modulators. | 10-08-2009 |
20090317404 | REDUCTION AND PREVENTION OF CELL-ASSOCIATED HIV TRANSEPITHELIAL MIGRATION, MICROBIDES AND OTHER FORMULATIONS AND METHODS - A vaginal microbicide including scFv-type antibodies reduces or prevents transepithelial HIV transmission. As the antibodies, anti-CD 18 and/or anti-CD 11 antibodies (of the scFv type) are used. Preferably, anti-ICAM antibody also is used. The antibodies may be delivered to the to-be-protected epithelium using a bacterial delivery system such as a | 12-24-2009 |
20090324613 | Compositions and Methods for the Therapy and Diagnosis of Cytomegalovirus - The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection. | 12-31-2009 |
20100034830 | Rabies vaccine - The invention provides for an immunogenic rabies vaccine comprising a reduced vaccine dose and methods of pre- and post-exposure immunization with a reduced dose. The concentration of rabies vaccine antigen per dose is preferably less than 2.5 IU/mL. | 02-11-2010 |
20100040635 | NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES - The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules. | 02-18-2010 |
20100074906 | Antibodies Specific for Varicella Zoster Virus - The present invention provides novel antibody sequences that bind Varicella Zoster Virus (VZV) and neutralize VZV infection. The novel sequences can be used for the medical management of VZV infection, in particular for detecting the virus or for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of VZV infection. | 03-25-2010 |
20100080813 | NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF - The invention relates to antibodies, and antigen binding fragments thereof, that bind to hemagglutinin and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection. | 04-01-2010 |
20100086555 | NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF - The invention relates to antibodies and antigen binding fragments thereof, that bind to hemagglutinin and neutralize infection of at least two different group 1 subtypes or at least two different group 2 subtypes of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection. | 04-08-2010 |
20100086556 | USE OF HEMAGGLUTININ OF THE AFRICAN SWINE FEVER VIRUS AS AN ADJUVANT - The invention generally relates to the use of the hemagglutinin (HA) of African swine fever virus (ASFV) as an adjuvant to enhance the immune response against an antigen in a subject. The invention provides a gene construct comprising all or part of the encoding sequence of said HA fused to the encoding sequence of an antigen. The invention is applicable in human and animal health. | 04-08-2010 |
20100119524 | ADJUVANTED VACCINE - This invention relates to an immunogenic composition comprising an Orthopoxvirus antigen and an adjuvant, the adjuvant comprises a CPG-motif-containing oligonucleotide, and the therapeutic uses thereof. | 05-13-2010 |
20100143376 | Antibodies Specific for Rubella Virus - The present invention provides novel antibody sequences that bind and neutralize Rubella Virus (RuV). The novel sequences can be used for the medical management of RuV infection, in particular for detecting the virus or for preparing pharmaceutical compositions. The RuV-specific antigens recognized by such antibody sequences can be identified using novel phage libraries that display peptides. | 06-10-2010 |
20100143377 | PRODUCTS FOR PROPHYLAXIS AND/OR TREATMENT OF VIRAL DISEASES AND METHODS OF MAKING AND USING SAME - The invention relates to an immunoglobulin composition suitable for prophylaxis and/or treatment of a viral mediated disease, disorder or condition and to methods of its preparation. In one embodiment, the invention provides a potent intravenous immunoglobulin composition useful for the treatment or prevention of a West Nile virus mediated disease, disorder or condition. | 06-10-2010 |
20100150941 | HEMAGGLUTININ ANTIBODY AND USES THEREOF - Passive antibody therapy as a tool for both prophylaxis against—and treatment of—highly pathogenic H5N1 influenza virus, providing immediate immunity is described. It is provided by an antibody specific to hemagglutinin capable of neutralizing influenza viruses and methods of making and using the same, the methods and compounds described herein may be used in diagnostic, prophylactic and therapeutic methods. | 06-17-2010 |
20100166769 | High-yield Transgenic Mammalian Expression System for Generating Virus-like Particles - Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described. | 07-01-2010 |
20100172917 | Binding molecules against SARS-coronavirus and uses thereof - Described are binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The binding molecules are capable of specifically binding to SARS-CoV, and can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from SAR. | 07-08-2010 |
20100203063 | PESTIVIRUS SPECIES - The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further relates to detection methods, vaccine therapeutics, and diagnostic methods using the PMC virus or gene/protein sequences derived therefrom. | 08-12-2010 |
20100215667 | METHODS AND COMPOSITIONS OF TREATMENT FOR MODULATING THE IMMUNE SYSTEM OF ANIMALS - Methods and compositions are disclosed for the dietary modulation of the immune system and gut microbial response in animals. Applicant has identified that oral administration of a supplemental spray dried plasma purified from animal serum can modulate serum IgG levels for treatment in such things as diminished immune capacity, intestinal microbial balance, autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans. | 08-26-2010 |
20100239593 | RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM - The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them. | 09-23-2010 |
20100247549 | MONOCLONAL ANTIBODIES AGAINST DENGUE AND OTHER VIRUSES WITH DELETION IN FC REGION - The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (FcγR) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal. | 09-30-2010 |
20100247550 | SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS AND USES OF SAID REPLIKIN SCAFFOLDS - The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures. | 09-30-2010 |
20100266614 | ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES - Ultra high affinity antibodies with binding affinities in the range of 10 | 10-21-2010 |
20100297144 | MULTITYPE HPV PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF HUMAN PAPILLOMAVIRUS INFECTION - Embodiments of the invention are directed to methods and compositions of multitype HPV polypeptides. | 11-25-2010 |
20100316653 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF ORTHOPOXVIRUSES - In particular aspects, the invention provides a novel approach for the systematic analysis and identification of biologically relevant epitopes (SABRE). SABRE-identified polypeptides have diagnostic (e.g., polypeptide arrays, etc.) and/or therapeutic (e.g., vaccines, etc.) utility, and utility for developing monoclonal antibodies having diagnostic and/or therapeutic utility (e.g. for detecting and/or preventing orthopoxvirus infection). Preferred aspects provide high-throughput assays for detecting specific orthopoxvirus infection, for detecting orthopoxvirus-specific immune response, or for dual (parallel) determination of both orthopoxvirus immune response and orthopoxvirus infection. Additional preferred and surprising aspects provide novel high-throughput methods for detecting ‘protective immunity’ against orthopoxviruses (e.g., for detecting protective immunity against smallpox virus and monkeypox virus), based on anti-vaccinia virus serum antibody levels. The inventive diagnostic assays are rapid, high-throughput and suitable for ‘point-of-care’ implementations. | 12-16-2010 |
20100316654 | NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES - The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, including neutralizing antibodies against two or more of H1, H2, H3, H5, H7 and H9, such as, for example all of H1, H2, H3, and H5 subtypes, and methods and means for making such antibodies. More specifically, the invention concerns antibodies capable of neutralizing more than one, preferably all, isolates of an influenza A virus subtype. | 12-16-2010 |
20110002943 | USE OF ENTEROVIRUS FOR DIAGNOSTICS, TREATMENT AND PREVENTION OF DISEASE - The invention is based on the finding that enterovirus is present in body samples of patients with celiac disease. The invention opens up the possibility for using enteroviruses in diagnosing, preventing, treating and monitoring the treatment of celiac-related diseases. The invention relates to a method for diagnosing, treating and monitoring the treatment of a celiac-related disease. The invention also relates to the use of enteroviruses or components or antibodies thereof for producing a vaccine, and the use of anti-enterovirus compositions for preparing a pharmaceutical against said disease. | 01-06-2011 |
20110027293 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF VIRAL INFECTION BY TARGETING INTRACELLULAR TRAFFICKING - The present invention features methods and compositions for the treatment or inhibition of infection by human papillomavirus (HPV) in a subject by administering an agent (e.g., a small molecule or antibody) that binds the carboxy-terminal region of the HPV L2 protein and reduces or inhibits the binding of the L2 protein to an intracellular molecular motor protein (IMMP) or IMMP co-factor. The invention also features a method for treating or inhibiting an HPV infection by administering a nucleic acid molecule that, for example, decreases the expression of the HPV L2 protein. | 02-03-2011 |
20110027294 | Anti-Respiratory Syncytial Virus Antibodies, Antigens and Uses Thereof - Anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies, RSV F protein antigens and their uses are disclosed. | 02-03-2011 |
20110052601 | COMPOSITIONS COMPRISING ANTI-ICAM-1 ANTIBODIES - There is provided a method of preventing a respiratory infection by administering an effective amount of an agent for regulating ICAM-1 expression. Also provided is a composition for the prevention of respiratory infection including an agent which regulates ICAM expression. method of preventing RSV infection by administering an effective amount of an agent that interferes with the binding of RSV to ICAM-1. A method of preventing RSV infection by administering an effective amount of an agent that down regulates the expression of ICAM-1, thereby decreasing RSV binding to ICAM-1 is also provided. There is provided a method of treating RSV infection by administering an effective amount of an agent for down regulating ICAM-1 expression. A method of blocking RSV-ICAM-1 interaction by administering an effective amount of agents for blocking ICAM sites of binding is provided. Also provided is a compound for blocking RSV-ICAM-1 interaction including an agent for blocking ICAM sites of binding. | 03-03-2011 |
20110104178 | NOVEL AVIAN ASTROVIRUS - The present invention relates to the fields of veterinary virology and immunology. In particular the invention relates to a novel avian Astrovirus; to antibodies or fragments thereof against the novel virus; to antigenic preparations, proteins, and DNA molecules of the novel avian Astrovirus; to vaccines of the novel virus or its antigenic preparations, protein, or DNA; to methods for the manufacture of such vaccines, and to diagnostic kits. | 05-05-2011 |
20110117109 | CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES - The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell. | 05-19-2011 |
20110123546 | Compositions Comprising Antibodies or Antibody Fragments - The present invention relates to food products or pharmaceutical preparations comprising a synergistic combination of at least two different antibodies or antibody fragments which are directed against a virus, preferably against rotavirus. | 05-26-2011 |
20110123547 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (II) | 05-26-2011 |
20110135659 | Fish Vaccine - A salmonid alphavirus polypeptide comprising an epitope capable of inducing a virus neutralizing immune response, nucleic acids encoding the polypeptide, a vaccine comprising the polypeptide and a method of producing salmonid alphavirus neutralizing antibodies. | 06-09-2011 |
20110142854 | COMPOSITIONS AND METHODS FOR INHIBITION OF RETROVIRUSES - Described herein are methods and compositions for the inhibition of retroviral integration and replication. The methods and compositions inhibit the activity of one or more components of the SET complex or base excision repair enzymes and induce autointegration of retroviral double-stranded nucleic acid. | 06-16-2011 |
20110142855 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) | 06-16-2011 |
20110150904 | Therapeutic Antibodies for Treatment and Prophylaxis of Transmittable Viral Diseases - The invention provides methods and compositions for the treatment and prevention of a transmittable disease in a subject, such as avians and mammals. The methods and compositions of the invention specifically make use of avian antibodies to the disease to be treated or prevented. Administration of such avian antibodies to a subject has been shown effective for reducing mortality in a population of subjects that are infected, or become infected, with the disease. The invention also provides kits useful for detecting the presence of transmittable diseases in subjects. | 06-23-2011 |
20110171233 | Antibodies Against Human Cytomegalovirus (HCMV) - The present invention provides novel antibodies sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections. | 07-14-2011 |
20110195075 | USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN - Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which including the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present of the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administering. Compositions contain isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a. | 08-11-2011 |
20110212105 | METHOD TO BLOCK THE INFECTION BY FLAVIVIRUSES, MOLECULES AND USES - The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin. | 09-01-2011 |
20110243962 | THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES - The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6. | 10-06-2011 |
20110268746 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 11-03-2011 |
20110274702 | NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF - The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection. | 11-10-2011 |
20110305708 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CYTOMEGALOVIRUS - The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection. | 12-15-2011 |
20110318363 | Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity - Described are single-stranded new sequences of TT viruses, rearranged TTV sequences and hybrid molecules of a specific TT virus sequence and host cell DNA that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use of such molecules as gene vectors and artificial chromosomes. | 12-29-2011 |
20110318364 | NONAPEPTIDE WITH ANTI-TUMOUR ACTIVITY - The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents. | 12-29-2011 |
20120003238 | Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (I) - Some coxsackie B viruses have been found to have a protective effect on type 1 diabetes, while others increase the risk of the disease. This opens up new therapeutic implications in the form of vaccines. The protective viruses CBV3, CBV4, CBV5 and CBV6 may be used in live attenuated vaccines for preventing or treating type 1 diabetes. They may also be used for inducing an immune response against risk viruses like CBV1, and for eliminating the diabetogenic effect of the risk viruses. Type 1 diabetes may be prevented especially by vaccinating with live attenuated protective viruses CBV3, CBV4, CVB5 and CBV6, and further with inactivated diabetogenic/risk virus CBV1, components thereof or antibodies thereto. | 01-05-2012 |
20120003239 | Enterovirus Vaccines for Preventing and Treating Type 1 Diabetes (II) - New enteroviruses associated with type 1 diabetes have been found, which opens up new therapeutic and diagnostic implications. A vaccine against at least one enterovirus selected from coxsackie A virus CAV4, CAV5, CAVE and echovirus 18 is provided for use in preventing or treating type 1 diabetes. A diagnostic assay for predicting the risk of contracting type 1 diabetes based on the determination of said enteroviruses is also provided. | 01-05-2012 |
20120003240 | Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (III) - Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic. | 01-05-2012 |
20120009202 | TARGET HOST FACTORS FOR TREATING VIRAL INFECTION - A method of reducing virus-mediated cytotoxicity comprising contacting virus-infected cells with an effective amount of at least one inhibitor of ABI2, ARRDC3, BAD, BRCA1, C17orf85, C1orf71, C6orf162, CCNJL, CFL1, GON4L, HCG 1986447, HIST1H2AB, HPS4, LHX8, RPS25, RPL23, RPL32, LOC730139, LRRC39, MALT1, MX1, MERTK, MX2, NRG1, OR52A1, PLEKHH1, PTPN13, PTPRJ, RLN1, RNF19A, SH3BP4, SLC7A14, ST8SIA3, STX3, TMC6, TMTC4, TNFSF12-TNFSF13, TNFSF13, TTN, UBXN7, USP47, WNK2, YPEL2, ZNF251 and/or SCG2. | 01-12-2012 |
20120014972 | INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES - The disclosure relates at least in part to embodiments of compositions and methods including vaccines for protection against multiple serologically distinct strains of influenza virus. This disclosure provides significant advances and addresses important needs in the influenza vaccine field. | 01-19-2012 |
20120027776 | DIABETIC MODEL - An isolated nucleic acid molecule is disclosed, including a nucleotide sequence selected from the nucleotide sequence of (a) Ljungan virus 87-012, (b) Ljungan virus 145SL, (c) Ljungan virus 174F, and (d) a fragment of nucleotide sequences (a)-(c). Also disclosed are polypeptides encoded by the isolated nucleic acid, which are useful in preparing vaccines and antibodies to prevent or inhibit conditions caused by Ljungan virus, including diabetes. | 02-02-2012 |
20120027777 | LJUNGAN VIRUS WITH IMPROVED REPLICATION CHARACTERISTICS - The present invention relates to a Ljungan virus with improved replication characteristic and the use of this Ljungan virus, amongst other thing, in the production of a vaccine. | 02-02-2012 |
20120045456 | STABILIZED ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY FORMULATIONS - The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention. | 02-23-2012 |
20120058124 | INFLUENZA VIRUS-NEUTRALIZING ANTIBODY AND SCREENING METHOD THEREFOR - Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody. | 03-08-2012 |
20120070446 | RSV SPECIFIC BINDING MOLECULE - The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided. | 03-22-2012 |
20120070447 | METHODS OF ADMINISTERING / DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT - The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection | 03-22-2012 |
20120076801 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease. | 03-29-2012 |
20120076802 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease. | 03-29-2012 |
20120093834 | NEUTRALIZING MOLECULES TO VIRAL ANTIGENS - The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules. | 04-19-2012 |
20120107326 | NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES - The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, including neutralizing antibodies against two or more of H1, H2, H3, H5, H7 and H9, such as, for example all of H1, H2, H3, and H5 subtypes, and methods and means for making such antibodies. More specifically, the invention concerns antibodies capable of neutralizing more than one, preferably all, isolates of an influenza A virus subtype. | 05-03-2012 |
20120114664 | ANTIBODIES AGAINST H5N1 STRAINS OF INFLUENZA A VIRUS - Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambda light chain, and that are IgG antibodies (but not with a IgG1 heavy chain) that can neutralize a H5N1 strain of influenza A virus. | 05-10-2012 |
20120128691 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 05-24-2012 |
20120128692 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 05-24-2012 |
20120135006 | ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES - Ultra high affinity antibodies with binding affinities in the range of 10 | 05-31-2012 |
20120141502 | ANTIBODIES SPECIFIC TO E6 PROTEINS OF HPV AND USE THEREOF - The subject invention provides an antibody composition for detecting E6 protein of at least one HPV strain in a sample. The subject antibodies may be used to detect oncogenic HPV E6 proteins in a sample, and the antibodies find use in a variety of diagnostic and therapeutic applications, including methods of diagnosing and treating cancer. Kits for performing the subject methods and containing the subject antibodies are also provided. Also disclosed in the present invention is a method of generating an antibody that specifically binds to amino-terminus of E6 proteins of at least two HPV strains. | 06-07-2012 |
20120141503 | Heavy Chain and Domain Antibodies - The present invention related to heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, suitable for use in the management of infections, in particular gastrointestinal tract. The present invention also relates to a delivery system comprising these heavy chain immunoglobulins or functional fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, and hosts comprising expression vectors encoding for these heavy chain immunoglobulins or functional fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof. The invention also related to food products and pharmaceutical preparations comprising the delivery system, and method for the preparation of food products according to the invention. | 06-07-2012 |
20120164155 | CHIMERIC MOLECULES - The invention relates to chimeric proteins comprising an antigen and a trimer forming portion or a trimer and virus-like particle forming portion of foamy virus envelope protein (FV TM). The trimer or trimer and virus-like particle forming portion comprises i) full length foamy virus transmembrane protein; ii) foamy virus transmembrane protein absent a functional cytoplasmic domain; iii) foamy virus transmembrane protein absent a functional cytoplasmic domain and transmembrane domain; iv) foamy virus ectodomain comprising N-terminal heptad repeat region and cysteine rich region between N-terminal heptad repeat region and C-terminal α-helical region; v) N-terminal heptad repeat region; vi) a functional variant of any one of i) to v); or vii) any one of i) to vi) lacking an FV fusion peptide domain. In particular, the antigen is an antigen of a virus envelope protein, such as HIV gp 120. Soluble and membrane bound forms of trimeric and higher oligomeric forms of the chimeric proteins are provided as well as nucleic acid molecules encoding and expressing same, viral-like particles comprising same, compositions including pharmaceutical compositions, host cells and kits. Methods are described for producing immune responses including antibodies determined by the chimeric protein or VLP, as well as methods of screening using the chimeric protein, VLP and/or antibodies. | 06-28-2012 |
20120195911 | Method of treatment of cancer patients - This invention may be used in human and veterinary medicine in combination with traditional methods of treatment of oncological illnesses for the purpose of increasing their effectiveness. | 08-02-2012 |
20120237527 | Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus - Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated. | 09-20-2012 |
20120263734 | Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections - The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection. | 10-18-2012 |
20120276115 | HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H5N1 AND USES THEREOF - Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated. | 11-01-2012 |
20120282273 | RECOMBINANT ANTIBODIES AGAINST H1N1 INFLUENZA - Antibodies that bind with high affinity to swine H1N1 virus are described. In vivo experiments showed that one such antibody is able to fully protect mice challenged with a lethal dose of swine H1N1 virus. The antibody is also able to cure mice in a therapeutic setting when treated as late as up to 60 hours (2.5 days) after infection with swine H1N1 virus. Also described are recombinant forms of this antibody. | 11-08-2012 |
20120288510 | HUMAN ANTIBODIES AGAINST HEPATITIS C VIRUS (HCV) AND USES THEREOF - Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 11-15-2012 |
20120301479 | HENDRA VIRUS RECOMBINANT COMPOSITIONS AND USES THEREOF - The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions. | 11-29-2012 |
20120308579 | METHOD OF MAKING AND USING A COMPOSITION FOR DELIVERING VIRAL IMMUNOGEN IMMUNOGLOBULIN INHIBITOR TO THE NASAL PHARYNGEAL MEMBRANE - A method of making and using an immunoglobulin package containing one or more viral inhibitors specifically targeted to receptor factors in viruses is provided. The immunoglobulin package substantially prevents the binding of viral immunogens in respiratory tracts of humans or animals and mechanically prevents a virus from reproducing in the nasal cavity. The immunoglobulins are made by inoculating cows with the immunogen(s), allowing the immune response to develop in the animal, harvesting the plasma containing the immunoglobulins, manufacturing the plasma to create a gel or liquid to swab, spray or mist into the nostril of the host. This method will prevent the spread of disease and give the host time to produce their own immunity to the virus for future protection. The invention may be utilized to substantially reduce or eliminate viruses that decrease the health of humans or animals such as Influenza and other respiratory viruses. | 12-06-2012 |
20120328626 | METHOD FOR INCREASING N-GLYCOSYLATION SITE OCCUPANCY ON THERAPEUTIC GLYCOPROTEINS PRODUCED IN PICHIA PASTORIS - Described is a method for increasing the N-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the N-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex, for example, the | 12-27-2012 |
20130022618 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 01-24-2013 |
20130028913 | ANTIBODY THAT BINDS TO H-1 PARVOVIRUS - Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops. | 01-31-2013 |
20130039926 | HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF - Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein. | 02-14-2013 |
20130039927 | ANTIGENIC MIMICS OF DISCONTINUOUS EPITOPES OF PATHOGEN RECOGNIZED BY BROADLY NEUTRALIZING ANTIBODIES - The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation. | 02-14-2013 |
20130058952 | ANTI-HSV ANTIBODY - The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims. | 03-07-2013 |
20130078261 | ENVELOPED VIRUS VACCINE AND METHOD FOR PRODUCTION - The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen. | 03-28-2013 |
20130101604 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease. | 04-25-2013 |
20130108649 | MODULATION OF UL24 INTERACTIONS WITH PROTEIN TARGETS AND USES THEREOF FOR INHIBITION OF HERPESVIRUS INFECTION | 05-02-2013 |
20130129747 | CROSS-PROTECTIVE PATHOGEN PROTECTION, METHODS AND COMPOSITIONS THEREOF - The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved sites that are not normally immunogenic for antibodies. Also disclosed herein are assays for detecting cross-protective antibodies, methods of generating novel cross-protective antibodies. Further provided are novel antibodies against influenza. | 05-23-2013 |
20130156791 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS - The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing human immunodeficiency virus type 1 (HIV-1) infection. More particularly, the present invention relates to a blocking agent of a component of the purinergic signalling pathway selected from the group consisting of pannexin 1, ATP or P2Y2 receptor for use in the treatment or prevention of HIV-1 infection. | 06-20-2013 |
20130164306 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS - Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided. | 06-27-2013 |
20130164307 | USE OF CAMELID-DERIVED VARIABLE HEAVY CHAIN VARIABLE REGIONS (VHH) TARGETING HUMAN CD18 AND ICAM-1 AS A MICROBICIDE TO PREVENT HIV-1 TRANSMISSION - The invention provides methods, compositions, and kits featuring a camelid-derived antibody for use in preventing or inhibiting a viral infection. | 06-27-2013 |
20130171169 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease. | 07-04-2013 |
20130177573 | ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USE - Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided. | 07-11-2013 |
20130189279 | Binding Molecules Against Chikungunya Virus and Uses Thereof - The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules. | 07-25-2013 |
20130195892 | BVDV VACCINE - The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines. | 08-01-2013 |
20130195893 | USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN - Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present on the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a. | 08-01-2013 |
20130202617 | HEMORRHAGIC FELINE CALICIVIRUS, CALICIVIRUS AND METHOD FOR PREVENTING CALICIVIRUS INFECTION OR DISEASE - The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen. | 08-08-2013 |
20130243792 | HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF - Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections. | 09-19-2013 |
20130295114 | PVRL4 (Nectin4) is a Receptor for Measles Virus - PVRL4 is a tumor marker that is highly expressed on the surfaces of many carcinomas. Disclosed herein are compositions and methods that provide impetus for using measles virus as an oncolytic agent against PVRL4+ carcinomas and use of PVRL4-binding agents to interfere with viral infection. | 11-07-2013 |
20130302348 | AGENTS FOR INFLUENZA NEUTRALIZATION - The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza. | 11-14-2013 |
20130302349 | NOVEL HA BINDING AGENTS - This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use. | 11-14-2013 |
20130302350 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 11-14-2013 |
20130302351 | ANTAGONISM OF THE VIP SIGNALING PATHWAY - The disclosure relates to inhibition of the VIP signaling pathway. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof. | 11-14-2013 |
20130309248 | HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H3N2 AND USES THEREOF - Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated. | 11-21-2013 |
20130315929 | VACCINE ANTIGENS THAT DIRECT IMMUNITY TO CONSERVED EPITOPES - A method of identification and elimination of immunodominant epitopes to elicit a response to secondary epitopes, especially conserved structures, is described, and applied to influenza haemagglutinin (HA). Identification of the primary epitopes in (HA), and replacement of amino acids having high LODrps with corresponding low LODrps amino acids produces an HA molecule which induces antibody responses to conserved HA residues. Modified HA molecules induce a broadly neutralizing vaccine. | 11-28-2013 |
20130330358 | CRYSTAL STRUCTURE AND PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE - Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating cancer through regulation of p53 activity in a cancer cell. Also disclosed is the crystalline structure of vIRF4-HAUSP TRAF domain complex. The structure is useful in computer aided drug design for identifying an agent that interacts with and inhibits HAUSP, resulting in p53 medicated cell cycle arrest of cancer cells. | 12-12-2013 |
20140017257 | IgY From Norovirus P Particles And Their Derivatives - A method for large-scale production of anti-NoV antibodies for use as a potential treatment for NoV disease using passive immunization. NoV-specific immunoglobulins (IgY) can be produced by immunizing chickens with NoV P particles. The birds continuously produced high titers of antibodies in their eggs for at least 3 months, in which NoV-specific antibody levels reached 4.7-9.2 mg/egg yolk. The egg yolk antibodies strongly reacted with NoV P particles by both ELISA and Western blot and blocked NoV virus-like particle (VLP) and P particle binding to the histo-blood group antigen (HBGA) receptors with a BT | 01-16-2014 |
20140037648 | ANTIBODIES THAT NEUTRALIZE RSV, MPV AND PVM AND USES THEREOF - The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both RSV, MPV and PVM. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to polypeptides that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV or MPV infection and RSV and MPV co-infection. | 02-06-2014 |
20140056913 | ANTI-DENGUE VIRUS ANTIBODIES AND USES THEREOF - The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV. | 02-27-2014 |
20140056914 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease. | 02-27-2014 |
20140065165 | HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF - Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections. | 03-06-2014 |
20140065166 | Neutralizing Antiboides to Nipah and Hendra Virus - The invention described herein provides novel peptides. The novel peptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Nipah virus and/or Hendra virus. | 03-06-2014 |
20140072575 | RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM - The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them. | 03-13-2014 |
20140093518 | Chemically Programmed Vaccination - Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound. | 04-03-2014 |
20140120113 | HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUSES OF PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUSES - The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses. | 05-01-2014 |
20140154265 | ARTERIVIRUS - The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes. | 06-05-2014 |
20140161822 | ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE - The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. | 06-12-2014 |
20140170163 | MONOCLONAL ANTIBODIES AGAINST INFLUENZA VIRUS GENERATED BY CYCLICAL ADMINISTRATION AND USES THEREOF - Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease. | 06-19-2014 |
20140178405 | MONOMERIC VHH DOMAIN DERIVED FROM ANTI-VP6 CAMELID ANTIBODIES, DIMERIC DOMAIN, IMMUNISATION METHOD, ROTAVIRUS DETECTION METHOD, COMPOSITION, PREVENTION AND TREATMENT METHODS FOR ROTAVIRUS INFECTIONS - Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunisation method, rotavirus detection method, vaccine composition, prevention and treatment methods for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, and wherein said domains bind to protein VP6 of Group A rotavirus. | 06-26-2014 |
20140186370 | VACCINIA VIRUS H3L AND B5R SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF MAKING AND USING SAME - The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof. | 07-03-2014 |
20140193428 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 07-10-2014 |
20140205614 | NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES - The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, including neutralizing antibodies against two or more of H1, H2, H3, H5, H7 and H9, such as, for example all of H1, H2, H3, and H5 subtypes, and methods and means for making such antibodies. More specifically, the invention concerns antibodies capable of neutralizing more than one, preferably all, isolates of an influenza A virus subtype. | 07-24-2014 |
20140205615 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 07-24-2014 |
20140212434 | MULTIVALENT VACCINES FOR RABIES VIRUS AND FILOVIRUSES - The present invention provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a filovirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a filovirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present invention provides a recombinant rabies virus vector omprising a nucleotide sequence encoding at least one filovirus glycoprotein or an immunogenic fragment thereof, as well as pharmaceutical compostions comprising the vaccine vectors. | 07-31-2014 |
20140234336 | Binding Molecule Having Influenza A Virus-Neutralizing Activity Produced from Human B Cell - The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention. | 08-21-2014 |
20140248285 | METHOD FOR PROTECTING PARVOVIRUS ANTIGEN - An improved method for the detection of parvovirus B19 in a sample is provided, the improvement consisting of detecting a parvovirus B19 non-structural protein in said sample. | 09-04-2014 |
20140248286 | ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE - The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. | 09-04-2014 |
20140255425 | Multi-CBV Vaccine for Preventing or Treating Type I Diabetes - The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided. | 09-11-2014 |
20140302062 | HERPES SIMPLEX VIRUS - The present invention relates, in general to herpes simplex virus (HSV) and, particular, to antibodies that are specific for glycoprotein D (gD) of HSV. The invention also relates to prophylactic and therapeutic uses of such antibodies. | 10-09-2014 |
20140302063 | INFLUENZA VIRUS ANTIBODY COMPOSITIONS - The present invention relates to unique CDR3 amino acid sequences, and to antibodies comprising said sequences. Also provided are therapeutic applications of said antibodies for use in treating or preventing influenza infection, diagnostic applications of said antibodies for use in detecting influenza virus, potency testing of influenza virus vaccines, and screening applications of said antibodies for use in designing a universal influenza vaccine. | 10-09-2014 |
20140341929 | HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF - Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections. | 11-20-2014 |
20140348858 | MONOCLONAL ANTIBODIES SPECIFIC FOR THE M2-1 ANTIGEN OF RESPIRATORY SYNCYTIAL VIRUS (RSV) - The use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, to a monoclonal antibody IgG2A secreted by the cell line of 8A4/G9 hybridoma specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. The antibodies are in the pure state and do not contain any other contaminating biological material. A method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a given host is provided, including the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease. The antibody can be humanized in order to minimize the possibility of an immune response against the same in the patient. In addition, it can be used to obtain any pharmaceutical form of the formulation of the monoclonal antibodies secreted by the 8A4/G9 hybridoma, which are suitable for the treatment or prevention of the disease caused by RSV. It also provides methods for detection and diagnosis of RSV viral antigens in biological samples using the monoclonal antibodies produced and secreted by cells of the 8A4/G9 hybridoma. | 11-27-2014 |
20140370032 | Multi-strain-reactive Antibodies for Therapy and Diagnosis of Influenza - The invention relates to a method for isolating a polypeptide reactive to influenza A hemagglutinin, comprising the steps of preparing a library of nucleic acid sequences, wherein each member of said library is attached to a polypeptide sequence encoded thereby, selecting members of said library by contacting the members with a panning antigen, wherein the panning antigen comprises a hemagglutinin stem region polypeptide sequence, subsequently removing members unreactive to the panning antigen, and selecting a member of said library by determining its binding to at least 5 influenza A hemagglutinin subtypes of subtype group 1 and 2. The invention further relates to polypeptides, particularly antibodies, obtainable by this method, that neutralize at least five influenza A subtypes of subtype group 1 and 2, to vaccines and uses thereof. | 12-18-2014 |
20140377279 | RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM - The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them. | 12-25-2014 |
20140377280 | NON-SIALYLATED ANTI-INFLAMMATORY POLYPEPTIDES - This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders. | 12-25-2014 |
20150037352 | NOVEL HA BINDING AGENTS - This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use. | 02-05-2015 |
20150071946 | TUMOR-SPECIFIC RETROTRANSPOSON INSERTIONS - Described are biomarkers for neoplastic disease progression. Specifically, provided are methods of determining neoplastic disease progression by determining the presence of retrotransposon insertion. | 03-12-2015 |
20150104466 | CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES - The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell. | 04-16-2015 |
20150118250 | MULTIVALENT RECOMBINANT AVIAN HERPES VIRUSES AND VACCINES FOR IMMUNIZING AVIAN SPECIES - The present invention relates to a recombinant | 04-30-2015 |
20150290314 | MARKER VACCINE - The present invention relates to replication-competent Bovine viral diarrhoea viruses (BVDV), Classical Swine Fever viruses (CSFV), Ovine Border Disease viruses (BDV) and atypical pestiviruses having a modification in an epitope of a viral protein, to their use as a medicament, to their use as a vaccine, to vaccines comprising such replication-competent BVDV, CSFV, atypical pestiviruses or BDV and to diagnostic tests for the detection of antibodies against such viruses and for distinguishing vaccinated animals from field infected animals | 10-15-2015 |
20150299297 | Passive Immunisation Against Influenza, In Particular H5N1 - The invention relates to a composition comprising immunoglobulins specific to influenza virus and produced through immunization of a producer animal, for use as a medicament for the passive immunisation of a human against an infection by an influenza virus, wherein the medicament is administered to the human in at least 1 dose before exposition or risk of exposition to an influenza virus and/or after exposition or risk of exposition to an influenza virus, and wherein the overall amount administered to the human in one or more doses is at least 20 μg of immunoglobulins per kg body weight. When the composition is for use after exposition or risk of exposition to an influenza virus, it is preferably administered to the human in at least 2 doses after exposition or risk of exposition to an influenza virus. | 10-22-2015 |
20150313988 | ARTERIVIRUS - The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes. | 11-05-2015 |
20150368321 | NOVEL FULL SPECTRUM ANTI-DENGUE ANTIBODY - The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV. | 12-24-2015 |
20160002318 | HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF - Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections. | 01-07-2016 |
20160074501 | Flavivirus virus like particle - Provided is a virus like particle comprising one or more flavivirus structural proteins, and a composition or vaccine comprising thereof, its use in the prevention or treatment of flavivirus infection. The flavivirus structural protein contains at least one amino acid alteration in the envelope region. Examples of flavivirus contains dengue virus. | 03-17-2016 |
20160096882 | NEUTRALIZING MOLECULES TO INFLUENZA VIRUSES - The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies. | 04-07-2016 |
20160137721 | ANTIBODIES AGAINST INFLUENZA VIRUS HEMAGGLUTININ AND USES THEREOF - Provided herein are antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes and methods of using such antibodies to diagnose, prevent or treat influenza virus disease. | 05-19-2016 |
20160145322 | HUMAN ANTIBODIES BINDING TO RSV G PROTEINS - The disclosure provides isolated antibodies and antigen-binding fragments that bind to the G protein of RSV and which are capable of neutralizing RSV. | 05-26-2016 |
20160166711 | RABIES VACCINE | 06-16-2016 |
20160193321 | MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS | 07-07-2016 |
20160199478 | ENVELOPED VIRUS VACCINE AND METHOD FOR PRODUCTION | 07-14-2016 |
20160200802 | ANTIBODIES THAT POTENTLY NEUTRALIZE RSV AND USES THEREOF | 07-14-2016 |
20160251413 | ANTIBODY MOLECULES TO DENGUE VIRUS AND USES THEREOF | 09-01-2016 |
20220135653 | Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections - A topical intranasal antiviral composition for protecting against virus infections. The composition comprises an antigen binder and a pharmaceutical suspender material to allow effective delivery into the nasal cavity. Examples of materials that could be used in the pharmaceutical suspender are microcrystalline cellulose or sodium carboxymethylcellulose (Na⋅CMC). One particular target for the antigen binder could be SARS-CoV-2. For example, the antigen binder could target the S1 subunit of SARS-CoV-2. The composition could be made by a process in which the pharmaceutical vehicle is prepared, and then the antigen binder is added to the pharmaceutical vehicle to make a bioactive mixture, and then adding solid sodium chloride to the bioactive mixture. Also disclosed are methods of protection against virus infection using the intranasal antiviral composition. For example, in the case of SARS-CoV-2, the antigen binder would block the virus particles from attaching to ACE2 receptors on host cells of the nasal mucosa or nasopharynx. This blocking action would protect against virus infection. | 05-05-2022 |